Icatibant Stada

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as an injectable solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema caused by C1‑inhibitor deficiency in patients who experience acute swelling attacks. GNH USA supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to control swelling associated with hereditary angioedema. - Hereditary angioedema (C1 inhibitor deficiency): reduces the severity and duration of acute swelling episodes. - Hereditary angioedema type I and II: provides rapid relief of symptoms by blocking bradykinin‑mediated vascular permeability.

Icatibant may cause a range of adverse reactions, most of which are related to its subcutaneous administration and its pharmacologic action.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or erythema: localized skin reddening. - Swelling at injection site: transient local edema. - Nausea: occasional gastrointestinal upset. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, pruritus, or urticaria. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Severe hypotension: marked drop in blood pressure. - Angioedema unrelated to hereditary condition: unexpected swelling. - Thrombocytopenia: reduced platelet count. - Severe injection‑site necrosis: rare tissue damage.

When using Icatibant, clinicians should observe several safety measures to minimize risk. - Hypersensitivity monitoring: watch for signs of allergic reaction during and after injection. - Cardiovascular caution: use carefully in patients with unstable blood pressure or heart disease. - Pregnancy safety: the effect in pregnancy is unknown; avoid unless clearly needed. - Breastfeeding: insufficient data; consider risks versus benefits. - Concomitant bradykinin‑modulating drugs: assess for additive effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that influence the bradykinin system or cardiovascular status.

Major Interactions (Avoid): - ACE inhibitors: may increase bradykinin levels and exacerbate swelling. - Angiotensin receptor blockers (ARBs): similar risk of elevated bradykinin. - Neprilysin inhibitors: can raise bradykinin concentrations.

Moderate Interactions (Monitor Closely): - DPP‑4 inhibitors: potential additive effect on bradykinin pathways. - Estrogen‑containing therapies: may alter angioedema frequency. - Other subcutaneous biologics: monitor injection‑site reactions when administered concurrently.